Insider Buying: Opko Health CEO Acquires 31,000 Shares of Stock (OPK)
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 31,000 shares of the stock on the open market in a transaction dated Friday, August 22nd. The stock was purchased at an average cost of $8.81 per share, with a total value of $273,110.00. Following the purchase, the chief executive officer now directly owns 2,012,377 shares of the company’s stock, valued at approximately $17,729,041. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Opko Health (NYSE:OPK) traded up 0.45% during mid-day trading on Monday, hitting $8.85. 1,458,969 shares of the company’s stock traded hands. Opko Health has a one year low of $7.32 and a one year high of $12.95. The stock’s 50-day moving average is $8.92 and its 200-day moving average is $8.83. The company’s market cap is $3.798 billion.
Opko Health (NYSE:OPK) last announced its earnings results on Monday, August 11th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the previous year, the company posted ($0.01) earnings per share. The company’s revenue for the quarter was down 1.3% on a year-over-year basis. Analysts expect that Opko Health will post $-0.31 EPS for the current fiscal year.
A number of analysts have recently weighed in on OPK shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, August 13th. They now have a $10.50 price target on the stock, down previously from $11.00. Finally, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Opko Health presently has a consensus rating of “Buy” and an average target price of $12.00.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.
Receive News & Ratings for Opko Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.